Obesity drug liraglutide tested on teens in Real-World study

NCT ID NCT07304141

Completed Knowledge-focused Sponsor: Göteborg University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study reviewed medical records of 128 teens aged 10-18 with obesity who were prescribed liraglutide (Saxenda) in Sweden. Researchers looked at changes in BMI and metabolic health over time. The goal is to see how the drug performs outside of controlled trials, in everyday clinical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Liraglutide (Saxenda)
What this could lead to: If successful, this could help doctors better understand how liraglutide works for teens with obesity in everyday care, potentially improving treatment guidelines.
What could go wrong: This is a small, retrospective study that only looks back at existing data, so it cannot prove cause and effect. Results may not apply to all teens.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHILD OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Pediatric Obesity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHILD OBESITY OBESITY (DISORDER)

Contacts and locations

Locations

the Regional Childhood Obesity Center, Queen Silvia's Children's Hospital.

Gothenburg, 416 50, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.